Recent Investment Analysts’ Ratings Updates for Sagimet Biosciences (SGMT)

A number of firms have modified their ratings and price targets on shares of Sagimet Biosciences (NASDAQ: SGMT) recently:

• 10/5/2026 – Sagimet Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
• 10/2/2026 – Sagimet Biosciences had its price target raised by Guggenheim from $25.00 to $26.00. They now have a “buy” rating on the stock.
• 10/1/2026 – Sagimet Biosciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 10/1/2026 – Sagimet Biosciences had its “market outperform” rating reaffirmed by Citigroup Inc..
• 10/1/2026 – Sagimet Biosciences had its price target raised by Oppenheimer Holdings, Inc. from $33.00 to $38.00. They now have an “outperform” rating on the stock.
• 10/1/2026 – Sagimet Biosciences had its price target lowered by Citizens Jmp from $29.00 to $27.00. They now have a “market outperform” rating on the stock.
• 9/28/2026 – Sagimet Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
• 9/24/2026 – Sagimet Biosciences is now covered by The Goldman Sachs Group, Inc.. They set a “sell” rating and a $7.00 price target on the stock.
• 9/24/2026 – Sagimet Biosciences is now covered by The Goldman Sachs Group, Inc.. They set a “sell” rating and a $7.00 price target on the stock.
• 9/9/2026 – Sagimet Biosciences is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $10.71 price target on the stock.
• 9/9/2026 – Sagimet Biosciences was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $18.00 price target on the stock, up from $8.00.
• 9/9/2026 – Sagimet Biosciences is now covered by Cantor Fitzgerald. They set an “overweight” rating and a $10.71 price target on the stock.
• 8/25/2026 – Sagimet Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $29.00 price target on the stock.
• 8/15/2026 – Sagimet Biosciences was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling at Sagimet Biosciences

In other news, CEO David Happel sold 64,051 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $7.76, for a total transaction of $497,035.76. Following the completion of the transaction, the chief executive officer directly owned 741,570 shares in the company, valued at approximately $5,754,583.20. This represents a 7.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director George Kemble sold 20,206 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $9.95, for a total value of $201,049.70. Following the transaction, the director owned 62,161 shares of the company’s stock, valued at approximately $618,501.95. This trade represents a 24.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 113,646 shares of company stock worth $920,491 in the last 90 days. 11.50% of the stock is owned by corporate insiders.

Sagimet Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company’s research is aimed at treating diseases associated with abnormal lipid metabolism and excess fat production.

Sagimet’s lead investigational product is denifanstat, an oral, selective FASN inhibitor formerly known as TVB-2640. The company is evaluating denifanstat primarily for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease that can involve inflammation, fat accumulation and fibrosis.